
Annual report 2025
added 03-30-2026
Cytosorbents Corporation Revenue 2011-2026 | CTSO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Cytosorbents Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.1 M | 35.6 M | 31.1 M | 9.39 M | 10.8 M | 12 M | 24.9 M | 22.5 M | 15.2 M | 9.53 M | 4.79 M | 4.12 M | 2.42 M | 1.34 M | 36.1 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.1 M | 36.1 K | 14.7 M |
Quarterly Revenue Cytosorbents Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.48 M | 9.62 M | 8.73 M | - | 8.61 M | 8.84 M | 8.99 M | - | 8.81 M | 9.42 M | 9.45 M | - | 8.11 M | 8.5 M | 8.69 M | 10.8 M | 9.76 M | 12 M | 10.6 M | 12 M | 10.5 M | 9.79 M | 8.71 M | 7.43 M | 6.1 M | 6.23 M | 5.19 M | 6.08 M | 5.74 M | 5.76 M | 4.92 M | 4.65 M | 3.82 M | 3.57 M | 3.11 M | 3.08 M | 2.41 M | 2.22 M | 1.81 M | 1.76 M | 1.34 M | 964 K | 723 K | 874 K | 1.16 M | 1.02 M | 1.06 M | - | 881 K | 291 K | 371 K | - | 605 K | 83 K | 50.2 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12 M | 50.2 K | 5.5 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 11.94 | -1.08 % | $ 1.61 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.07 | -3.3 % | $ 257 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 36.67 | -0.19 % | $ 5.46 K | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.58 | -0.11 % | $ 122 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.4 | -1.73 % | $ 127 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 90.0 | 1.58 % | $ 12.2 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
4 B | $ 166.87 | -2.91 % | $ 12.5 B | ||
|
AxoGen
AXGN
|
225 M | $ 30.99 | -5.06 % | $ 1.43 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.05 | -1.94 % | $ 857 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.67 | -0.31 % | $ 346 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.83 | -3.68 % | $ 1.11 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 61.86 | -1.12 % | $ 91.6 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 11.03 | 0.55 % | $ 1.66 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.33 | 0.21 % | $ 719 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 34.54 | 1.35 % | $ 1.07 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.03 | 3.35 % | $ 17.4 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.11 | -0.61 % | $ 2.96 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 80.84 | -0.43 % | $ 47.3 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 54.42 | 0.52 % | $ 1.6 B | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.76 | -1.13 % | $ 370 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.63 | -4.41 % | $ 67.3 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 86.42 | 0.15 % | $ 111 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.68 | -2.9 % | $ 28.5 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 11.71 | -0.51 % | $ 464 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M |